Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma
Clinical trial NCT00911560 · COMPLETED
Trial details
- NCT number
- NCT00911560
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2009-05-27
- Primary completion
- 2026-08-03
- Enrollment
- 374
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.